Literature DB >> 33477288

The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance.

Javier Martinez-Useros1, Mario Martin-Galan1, Jesus Garcia-Foncillas1.   

Abstract

In the last decade, several studies based on whole transcriptomic and genomic analyses of pancreatic tumors and their stroma have come to light to supplement histopathological stratification of pancreatic cancers with a molecular point-of-view. Three main molecular studies: Collisson et al. 2011, Moffitt et al. 2015 and Bailey et al. 2016 have found specific gene signatures, which identify different molecular subtypes of pancreatic cancer and provide a comprehensive stratification for both a personalized treatment or to identify potential druggable targets. However, the routine clinical management of pancreatic cancer does not consider a broad molecular analysis of each patient, due probably to the lack of target therapies for this tumor. Therefore, the current treatment decision is taken based on patients´ clinicopathological features and performance status. Histopathological evaluation of tumor samples could reveal many other attributes not only from tumor cells but also from their microenvironment specially about the presence of pancreatic stellate cells, regulatory T cells, tumor-associated macrophages, myeloid derived suppressor cells and extracellular matrix structure. In the present article, we revise the four molecular subtypes proposed by Bailey et al. and associate each subtype with other reported molecular subtypes. Moreover, we provide for each subtype a potential description of the tumor microenvironment that may influence treatment response according to the gene expression profile, the mutational landscape and their associated histology.

Entities:  

Keywords:  chemotherapy response; microenvironment; molecular subtypes of pancreatic cancer; myeloid derived suppressor cells; pancreatic stellate cells; regulatory T cells; tumor-associated macrophages

Year:  2021        PMID: 33477288      PMCID: PMC7829908          DOI: 10.3390/cancers13020322

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  117 in total

Review 1.  Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma.

Authors:  Dong Tang; Daorong Wang; Zhongxu Yuan; Xiaofeng Xue; Ye Zhang; Yong An; Jianmin Chen; Min Tu; Zipeng Lu; Jishu Wei; Kuirong Jiang; Yi Miao
Journal:  Int J Cancer       Date:  2012-10-05       Impact factor: 7.396

Review 2.  Pancreatic cancer: The microenvironment needs attention too!

Authors:  M V Apte; Z Xu; S Pothula; D Goldstein; R C Pirola; J S Wilson
Journal:  Pancreatology       Date:  2015-03-21       Impact factor: 3.996

3.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Authors:  Dung T Le; Andrea Wang-Gillam; Vincent Picozzi; Tim F Greten; Todd Crocenzi; Gregory Springett; Michael Morse; Herbert Zeh; Deirdre Cohen; Robert L Fine; Beth Onners; Jennifer N Uram; Daniel A Laheru; Eric R Lutz; Sara Solt; Aimee Luck Murphy; Justin Skoble; Ed Lemmens; John Grous; Thomas Dubensky; Dirk G Brockstedt; Elizabeth M Jaffee
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

4.  Regulatory T Cells Keep Pancreatic Cancer at Bay.

Authors:  Berk Aykut; Ruonan Chen; George Miller
Journal:  Cancer Discov       Date:  2020-03       Impact factor: 39.397

Review 5.  Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability.

Authors:  Robert G Bristow; Richard P Hill
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

6.  Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer.

Authors:  Xuguang Yang; Yun Lu; Junjie Hang; Junfeng Zhang; Tiening Zhang; Yanmiao Huo; Jun Liu; Songtao Lai; Dawei Luo; Liwei Wang; Rong Hua; Yuli Lin
Journal:  Cancer Immunol Res       Date:  2020-09-11       Impact factor: 11.151

7.  Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins.

Authors:  Hidenori Miyamoto; Tatsuya Murakami; Kunihiro Tsuchida; Hiromu Sugino; Hidenori Miyake; Seiki Tashiro
Journal:  Pancreas       Date:  2004-01       Impact factor: 3.327

8.  Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas.

Authors:  Toru Furukawa; Hitomi Sakamoto; Shoko Takeuchi; Mitra Ameri; Yuko Kuboki; Toshiyuki Yamamoto; Takashi Hatori; Masakazu Yamamoto; Masanori Sugiyama; Nobuyuki Ohike; Hiroshi Yamaguchi; Michio Shimizu; Noriyuki Shibata; Kyoko Shimizu; Keiko Shiratori
Journal:  Sci Rep       Date:  2015-03-06       Impact factor: 4.379

9.  SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities.

Authors:  Sabina Sangaletti; Giovanna Talarico; Claudia Chiodoni; Barbara Cappetti; Laura Botti; Paola Portararo; Alessandro Gulino; Francesca Maria Consonni; Antonio Sica; Giovanni Randon; Massimo Di Nicola; Claudio Tripodo; Mario P Colombo
Journal:  Front Immunol       Date:  2019-06-20       Impact factor: 7.561

View more
  8 in total

Review 1.  Current Pathology Model of Pancreatic Cancer.

Authors:  Krzysztof Szymoński; Katarzyna Milian-Ciesielska; Ewelina Lipiec; Dariusz Adamek
Journal:  Cancers (Basel)       Date:  2022-05-07       Impact factor: 6.575

2.  Integrating Network Pharmacology and Experimental Verification to Explore the Mechanism of Effect of Zuojin Pills in Pancreatic Cancer Treatment.

Authors:  Kunpeng Wang; Xiongying Miao; Fanhua Kong; Siqi Huang; Jinggang Mo; Chong Jin; Yanwen Zheng
Journal:  Drug Des Devel Ther       Date:  2021-09-04       Impact factor: 4.162

Review 3.  Nuclear Dynamics and Chromatin Structure: Implications for Pancreatic Cancer.

Authors:  Luis F Flores; Brooke R Tader; Ezequiel J Tolosa; Ashley N Sigafoos; David L Marks; Martin E Fernandez-Zapico
Journal:  Cells       Date:  2021-10-01       Impact factor: 6.600

Review 4.  Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report.

Authors:  Clelia Madeddu; Elisabetta Sanna; Sonia Nemolato; Olga Mulas; Sara Oppi; Mario Scartozzi; Giorgio La Nasa; Antonio Maccio
Journal:  Diagnostics (Basel)       Date:  2022-08-07

5.  Expression of lactate-related signatures correlates with immunosuppressive microenvironment and prognostic prediction in ewing sarcoma.

Authors:  Zhao Zhang; Jingxin Pan; Debin Cheng; Yubo Shi; Lei Wang; Zhenzhou Mi; Jun Fu; Huiren Tao; Hongbin Fan
Journal:  Front Genet       Date:  2022-08-24       Impact factor: 4.772

6.  Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine.

Authors:  Ryan N Fuller; Janviere Kabagwira; Paul A Vallejos; Andrew D Folkerts; Nathan R Wall
Journal:  Onco Targets Ther       Date:  2022-10-10       Impact factor: 4.345

Review 7.  Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma.

Authors:  Rita Rebelo; Bárbara Polónia; Lúcio Lara Santos; M Helena Vasconcelos; Cristina P R Xavier
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-20

Review 8.  Targeting the Stroma in the Management of Pancreatic Cancer.

Authors:  Penelope Edwards; Byung Woog Kang; Ian Chau
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.